FI3826667T3 - Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi - Google Patents
Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi Download PDFInfo
- Publication number
- FI3826667T3 FI3826667T3 FIEP18857242.4T FI18857242T FI3826667T3 FI 3826667 T3 FI3826667 T3 FI 3826667T3 FI 18857242 T FI18857242 T FI 18857242T FI 3826667 T3 FI3826667 T3 FI 3826667T3
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- antigen
- binding fragment
- amino acid
- cldn6
- Prior art date
Links
- 102000003859 Claudin-6 Human genes 0.000 title claims 12
- 108090000229 Claudin-6 Proteins 0.000 title claims 12
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 3
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000006143 cell culture medium Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560143P | 2017-09-18 | 2017-09-18 | |
| PCT/US2018/051610 WO2019056023A2 (en) | 2017-09-18 | 2018-09-18 | ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3826667T3 true FI3826667T3 (fi) | 2024-07-22 |
Family
ID=65723110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18857242.4T FI3826667T3 (fi) | 2017-09-18 | 2018-09-18 | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20200291111A1 (enExample) |
| EP (2) | EP3826667B1 (enExample) |
| JP (2) | JP7599332B2 (enExample) |
| KR (2) | KR102793719B1 (enExample) |
| CN (2) | CN111565744B (enExample) |
| AU (2) | AU2018334434B2 (enExample) |
| BR (1) | BR112020005196A2 (enExample) |
| CA (1) | CA3076207A1 (enExample) |
| CZ (1) | CZ2021138A3 (enExample) |
| DK (1) | DK3826667T3 (enExample) |
| ES (1) | ES2986343T3 (enExample) |
| FI (1) | FI3826667T3 (enExample) |
| GB (1) | GB202103867D0 (enExample) |
| HU (1) | HUE067603T2 (enExample) |
| IL (2) | IL273196B2 (enExample) |
| MX (2) | MX2020002921A (enExample) |
| NO (1) | NO20210351A1 (enExample) |
| PL (1) | PL3826667T3 (enExample) |
| PT (1) | PT3826667T (enExample) |
| SG (1) | SG11202002114RA (enExample) |
| SI (1) | SI3826667T1 (enExample) |
| WO (1) | WO2019056023A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO20210351A1 (en) * | 2017-09-18 | 2021-03-18 | Univ California | Claudin6 antibodies and methods of treating cancer |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| KR102063341B1 (ko) * | 2018-12-31 | 2020-01-07 | 다이노나(주) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
| AU2020223293A1 (en) | 2019-02-15 | 2021-08-19 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| SI3941946T1 (sl) * | 2019-03-20 | 2025-09-30 | The Regents Of The University Of California | Protitelesa proti klavdinu-6 in konjugati zdravil |
| CA3134056A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| JP2023529557A (ja) * | 2020-05-04 | 2023-07-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｎｐｐ１抗体の阻害 |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| KR20240153421A (ko) * | 2022-02-09 | 2024-10-22 | 세라 프로그노스틱스 인코포레이티드 | Shbg 및 ibp4 항체 및 이를 사용하는 방법 |
| KR20250114330A (ko) | 2022-11-30 | 2025-07-29 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
| WO2025075127A1 (ja) * | 2023-10-04 | 2025-04-10 | 公立大学法人福島県立医科大学 | がんのバイオマーカー及び抗体治療 |
| WO2025146161A1 (en) * | 2024-01-04 | 2025-07-10 | Hansoh Bio Llc | Antibody, antigen-binding fragment and medical use thereof |
| WO2025162270A1 (zh) * | 2024-02-01 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗cldn6抗体、其抗体-药物偶联物及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| CA1264738A (en) | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| KR20010040819A (ko) | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | 제어방출형 제제 |
| US6630124B1 (en) | 1998-10-16 | 2003-10-07 | Ramot-University Authority For Applied Research And Industrial Development Ltd. | Combination therapy with VIP antagonist |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2004033036A2 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| EP2103628A4 (en) * | 2006-12-14 | 2012-02-22 | Forerunner Pharma Res Co Ltd | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY |
| RU2422134C1 (ru) | 2007-04-19 | 2011-06-27 | Донг-А Фармасьютикал. Ко., Лтд | Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав |
| SG187457A1 (en) * | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| NZ724296A (en) * | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| DK3126381T4 (da) * | 2014-04-01 | 2022-04-04 | Biontech Cell&Gene Therapies Gmbh | Claudin-6-specifikke immunoreceptorer og t-celleepitoper |
| NO20210351A1 (en) * | 2017-09-18 | 2021-03-18 | Univ California | Claudin6 antibodies and methods of treating cancer |
-
2018
- 2018-09-18 NO NO20210351A patent/NO20210351A1/en not_active Application Discontinuation
- 2018-09-18 MX MX2020002921A patent/MX2020002921A/es unknown
- 2018-09-18 EP EP18857242.4A patent/EP3826667B1/en active Active
- 2018-09-18 KR KR1020207009742A patent/KR102793719B1/ko active Active
- 2018-09-18 CN CN201880073220.3A patent/CN111565744B/zh active Active
- 2018-09-18 CN CN202410853420.8A patent/CN118667021A/zh active Pending
- 2018-09-18 BR BR112020005196-9A patent/BR112020005196A2/pt unknown
- 2018-09-18 IL IL273196A patent/IL273196B2/en unknown
- 2018-09-18 IL IL313238A patent/IL313238A/en unknown
- 2018-09-18 GB GBGB2103867.4A patent/GB202103867D0/en active Pending
- 2018-09-18 US US16/648,428 patent/US20200291111A1/en not_active Abandoned
- 2018-09-18 ES ES18857242T patent/ES2986343T3/es active Active
- 2018-09-18 CA CA3076207A patent/CA3076207A1/en active Pending
- 2018-09-18 SG SG11202002114RA patent/SG11202002114RA/en unknown
- 2018-09-18 DK DK18857242.4T patent/DK3826667T3/da active
- 2018-09-18 EP EP24169481.9A patent/EP4435009A3/en active Pending
- 2018-09-18 FI FIEP18857242.4T patent/FI3826667T3/fi active
- 2018-09-18 JP JP2020515692A patent/JP7599332B2/ja active Active
- 2018-09-18 PT PT188572424T patent/PT3826667T/pt unknown
- 2018-09-18 HU HUE18857242A patent/HUE067603T2/hu unknown
- 2018-09-18 WO PCT/US2018/051610 patent/WO2019056023A2/en not_active Ceased
- 2018-09-18 AU AU2018334434A patent/AU2018334434B2/en active Active
- 2018-09-18 PL PL18857242.4T patent/PL3826667T3/pl unknown
- 2018-09-18 SI SI201831128T patent/SI3826667T1/sl unknown
- 2018-09-18 KR KR1020257011014A patent/KR20250050137A/ko active Pending
-
2020
- 2020-03-17 MX MX2025012685A patent/MX2025012685A/es unknown
-
2021
- 2021-03-19 CZ CZ2021138A patent/CZ2021138A3/cs unknown
-
2022
- 2022-04-13 US US17/719,609 patent/US20220372134A1/en not_active Abandoned
-
2023
- 2023-12-19 US US18/545,890 patent/US20240400674A1/en not_active Abandoned
-
2024
- 2024-06-20 JP JP2024099523A patent/JP2024150445A/ja active Pending
-
2025
- 2025-01-23 AU AU2025200467A patent/AU2025200467A1/en active Pending
- 2025-06-27 US US19/252,512 patent/US20250333501A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP6709215B2 (ja) | 抗ｔｉｍ−３抗体 | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20250850T1 (hr) | Antitijela protiv claudina 18.2 korisna u dijagnozi raka | |
| JP2018532383A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2021500916A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| JP2016516400A5 (enExample) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| JP2020534830A5 (enExample) | ||
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| EP2796466A3 (en) | Humanized antibody molecules specific for IL-31 | |
| JP2018505681A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| JP2015508056A5 (enExample) | ||
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use |